What guidance did aTyr Pharma's management provide for the next earnings period?

What were the key takeaways from aTyr Pharma's earnings call?

What is aTyr Pharma's gross profit margin?

What factors drove the changes in aTyr Pharma's revenue and profit?

What were the key takeaways from aTyr Pharma’s earnings call?

Did aTyr Pharma beat or miss consensus estimates last quarter?

What does aTyr Pharma do and what are its main business segments?

What is aTyr Pharma's latest dividend and current dividend yield?

- **Phase 3 Trial Milestone**: 268-patient EFZO-FIT study completed enrollment; steroid reduction now measured as absolute change from baseline.
- **Market Expansion**: Sarcoidosis patient population 30% higher than prior estimates, 75% on steroids; $2-5B ILD market potential.
- **Financial Strength**: $75.1M cash, extended runway to cover Phase 3 readout and BLA filing.
- **Scientific Validation**: Published in *Science Translational Medicine*; preclinical candidates target fibrosis in lungs, liver, and kidneys.
- **Commercial Readiness**: Board addition of Eric Benevich to accelerate launch planning.


**【CEO Summary Section】**
- Completed enrollment in the pivotal Phase 3 EFZO-FIT study for pulmonary sarcoidosis with 268 patients across 85 global sites. Top-line data expected Q3 2025.
- Transitioned to measuring steroid reduction as absolute change from baseline to week 48, simplifying analysis while maintaining >90% statistical power.
- Expanded Access Program (EAP) shows strong patient and investigator interest, with plans to present baseline demographics at ATS 2025.
- Market research suggests sarcoidosis patient population is 30% higher than previously estimated, with 75% of diagnosed patients on steroids.
- Appointed Eric Benevich, CCO of Neurocrine Biosciences, to the Board for commercial readiness support.

**【CFO Financial Commentary】**
- Ended 2024 with $75.1M in cash, raising an additional $18.8M via ATM post-Q4.
- R&D expenses: $54.4M (clinical trials, manufacturing, discovery programs).
- Collaborative revenue: $0.2M from Kyorin partnership, with potential $155M in future milestones.
- Cash runway extended to cover Phase 3 readout and BLA filing.

**【Research & Discovery】**
- Published in *Science Translational Medicine* detailing efzofitimod's mechanism targeting NRP2 to resolve inflammation without immune suppression.
- Preclinical candidates ATYR0101 (lung/kidney fibrosis) and ATYR0750 (liver disorders) show promise in fibrosis models.

**【Q&A Highlights】**
- Q: Impact of steroid reduction analysis change? A: Simplifies data interpretation, aligns with FDA feedback, preserves statistical rigor.
- Q: EAP participation rate? A: Strong interest, but country-specific regulatory hurdles limit exact metrics.
- Q: Market potential for efzofitimod? A: $2-5B global ILD market, with sarcoidosis driving near-term growth.
- Q: Manufacturing readiness? A: Transitioned to commercial-grade partner, on track for BLA submission.


aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

Atyr Pharma (LIFE)-14 Mar 24-2023 Q4 Earnings call transcript

Atyr Pharma (LIFE)-9 Mar 23-2022 Q4 Earnings call transcript

Atyr Pharma (LIFE)-11 Nov 22-2022 Q3 Earnings call transcript

Atyr Pharma (LIFE)-16 Aug 22-2022 Q2 Earnings call transcript

Atyr Pharma (LIFE)-10 May 22-2022 Q1 Earnings call transcript

Atyr Pharma (LIFE)-15 Mar 22-2021 Q4 Earnings call transcript

Atyr Pharma (LIFE)-11 Nov 21-2021 Q3 Earnings call transcript

Atyr Pharma (LIFE)-11 Aug 21-2021 Q2 Earnings call transcript

Atyr Pharma (LIFE)-14 May 21-2021 Q1 Earnings call transcript

Atyr Pharma (LIFE)-24 Mar 21-2020 Q4 Earnings call transcript

Atyr Pharma (LIFE)-13 Nov 20-2020 Q3 Earnings call transcript

Atyr Pharma (LIFE)-13 Aug 20-2020 Q2 Earnings call transcript

Atyr Pharma (LIFE)-12 May 20-2020 Q1 Earnings call transcript

Atyr Pharma (LIFE)-26 Mar 20-2019 Q4 Earnings call transcript

Atyr Pharma (LIFE)-14 Nov 19-2019 Q3 Earnings call transcript

Atyr Pharma (LIFE)-14 Aug 19-2019 Q2 Earnings call transcript

Atyr Pharma (LIFE)-13 May 19-2019 Q1 Earnings call transcript

Atyr Pharma (LIFE)-25 Mar 19-2018 Q4 Earnings call transcript

Atyr Pharma (LIFE)-13 Nov 18-2018 Q3 Earnings call transcript

Atyr Pharma (LIFE)-14 Aug 18-2018 Q2 Earnings call transcript

Atyr Pharma (LIFE)-14 May 18-2018 Q1 Earnings call transcript

Atyr Pharma (LIFE)-19 Mar 18-2017 Q4 Earnings call transcript

ATYR

ATYR fundamentals

Earnings Call

You can ask Aime